A Study of Carboplatin, PLD and Everolimus in Certain Gynecologic Cancer

Exclusion Criteria

• •Patients with more than one prior chemotherapy regimen for management of primary disease
• •Patients who have received a prior mammalian target of rapamycin (mTOR) inhibitor
• •Chronic treatment with systemic steroids or other immunosuppressive agents; Note: topical or inhaled steroids are allowed
• •Uncontrolled brain or leptomeningeal metastases, including those who continue to require glucocorticoids for brain or leptomeningeal metastases
• •Other malignancies =\< 3 years prior to registration except for adequately treated carcinoma of the cervix or basal or squamous carcinomas of the skin
• •Other concurrent severe and/or uncontrolled medical disease which could compromise participation in the study; examples include, but are not limited to: uncontrolled diabetes defined as fasting serum glucose \> 1.5 x ULN; uncontrolled hypertension, or greater than 150/100 in spite of antihypertensive therapy; active (acute or chronic) or uncontrolled severe infection; unstable angina pectoris, symptomatic congestive heart failure (New York Heart Association Class III or IV); ventricular arrhythmias, active ischemic heart disease, myocardial infarction within six months; liver disease such as cirrhosis, chronic active hepatitis or chronic persistent hepatitis
• •Known history of human immunodeficiency virus (HIV) seropositivity as these patients are at increased risk of lethal infections when treated with marrow-suppressive therapy and the potential pharmacokinetic interaction between antiretroviral therapy and the investigational agent
• •Known history of Hepatitis B or C as these patients may be at risk of disease reactivation when treated with the chemotherapy and/or the investigational agent
• •Patients should not receive immunization with attenuated live vaccines =\< 7 days of study entry or during study period
• •Impairment of gastrointestinal function or gastrointestinal disease that may significantly alter the absorption of RAD001 (i.e. ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome or small bowel resection sufficient to impair absorption of drug)
• •Patients with clinical symptoms of gastrointestinal obstruction and who require parenteral hydration/nutrition
• •Patients with an active bleeding diathesis
• •Women who are pregnant or breast-feeding, or women able to conceive and unwilling to practice an effective method of birth control; (women of childbearing potential must have a negative urine or serum pregnancy test within =\< 7 days prior to administration of RAD001); oral, implantable or injectable contraceptives may be affected by cytochrome P450 interactions and are therefore not considered effective for this study
• •History of noncompliance with medical regimens
• •Patients with a known hypersensitivity to any of the study agents
• •Patients unwilling or unable to comply with the outlined protocol
• •Patients with psychiatric illness or social situations that would limit compliance with study requirements